Antiangiogenesis agents in colorectal cancer

Current Opinion in Oncology

Volumn 22, Issue 4, 2010, Pages 374-380

  Hubbard, Joleen ^a   Grothey, Axel ^a  

^a MAYO CLINIC   (United States)

Author keywords

antiangiogenesis; colorectal adenocarcinoma; tyrosine kinase inhibitor

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CEDIRANIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DISEASE COURSE; DISEASE FREE SURVIVAL; GLIOBLASTOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; PRIORITY JOURNAL; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; COLORECTAL NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953915446     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328339524e     Document Type: Review

References (40)

1. Verheul HM, Voest EE, Schlingemann RO. Are tumours angiogenesis-de- pendent? J Pathol 2004; 202:5-13.
2. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
4. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.
5. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
6. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393-11398.
7. Camidge DR, Eckhardt SG, Diab S, et al. A phase I dose-escalation study of weekly IMC-1121B, a fully human antivascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer [abstract #3032]. J Clin Oncol 2006; 24 (18 Suppl).
8. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 [abstract #LBA4]. J Clin Oncol 2009; 27 (18 Suppl).
9. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27:3385-3390.
10. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27:872-877.
11. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231.
12. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
13. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-2019.
14. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006-2012.
15. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523-3529.
16. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oralfluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779-4786.
17. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-1544.
18. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26:5326-5334.
19. Purdie DM, Berlin JD, Flynn PJ, et al. The safety of long-term bevacizumab use: results from the BRiTE observational cohort study (OCS). J Clin Oncol 2008; 26 (20 Suppl).
20. Arnold D, Reinacher-Schick A, Muller L, et al. Bevacizumab (Bev) beyond progression (BP) in combination with second-line chemotherapy (CT) after failure of a Bev containing first-line CT in patients (pts) with metastastic colorectal cancer (mCRC). Preliminary baseline and safety analysis from the AIO 0504/AGMT phase III study [abstract #469]. Presented at 2008 Gastrointestinal Cancers Symposium; 2008.
21. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557-4561.
22. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemother apy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672-680.
23. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-572.
24. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6:569-579.
25. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 1998; 90:675-684.
26. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
27. Cassano A, Bagala C, Battelli C, et al. Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer. Anticancer Res 2002; 22:2179-2184.
28. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
29. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
30. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitortargeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337.
31. Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25:4793-4799.
32. Starling N, Vazquez F, Cunningham D, et al. Phase I study to evaluate the safety and efficacy of sunitinib in combination with FOLFIRI in treatment-näive metastatic colorectal cancer (mCRC) [abstract #3563]. J Clin Oncol 2008; 26 (Suppl).
33. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7:3129-3140.
34. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26:3709-3714.
35. Sharma S, Abhyankar V, Burgess RE, et al. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 2010; 21:297-304.
36. Chen E, Jonker D, Gauthier I, et al. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced color-ectal cancer. Clin Cancer Res 2009; 15:1481-1486.
37. Cunningham D, Wong RP, D'haens G, et al. A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizu-mab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results [abstract #4028]. J Clin Oncol 2008; 26 (Suppl).
38. Strumberg D, Scheulen ME, Frost A, et al. Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC) [abstract #3560]. J Clin Oncol 2009; 27 (15 Suppl).
39. Garrett CR, Siu LL, Giaccone G, et al. A phase I study of brivanib alaninate (BMS-582664),anoral dual inhibitorof VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy [abstract #4111]. J Clin Oncol 2008; 26 (Suppl).
40. Ayers M, Awad M, Malone D, et al. Correlation between K-ras status and efficacy results from a phase I/II study of brivanib alaninate in combination with cetuximab in patients (pts) with advanced or metastatic colorectal cancer (CRC) [abstract #375]. 2009 Gastrointestinal Cancers Symposium.